Lumos Diagnostics receives A$710,000 R&D tax rebate to support point-of-care technology development
Published: 21:14 28 Jun 2026 EDT
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received a A$709,837 cash refund under the Australian Government’s Research and Development Tax Incentive, strengthening its capacity to advance its rapid point-of-care diagnostic technology platforms.
The refund relates to eligible research and development expenditure for the FY25 financial year ended June 30, 2025, and is mainly associated with work on Lumos’ proprietary portable handheld and disposable reader technology platforms.
R&D refund supports innovation pipeline
The Australian Government’s R&D Tax Incentive provides eligible companies with cash refunds for up to 48.5% of qualifying research and development expenditure.
For Lumos, the rebate will support ongoing investment in technologies designed to improve the detection of a broader range of clinical biomarkers, enhance interpretation of point-of-care test results and enable smoother integration with electronic medical records.
The platforms are a key part of its value proposition and have played a role in securing contracts with partners including Hologic, Aptatek BioSciences and Micro-Pak.
Reader platform remains core focus
Lumos chief executive officer and managing director Doug Ward said the refund would help support continued investment in innovation and product development.
“We are pleased to receive this R&D tax refund, which supports our ongoing investment in innovation and product development. The funding assists with the evolution of our proprietary reader platform - a core component of our diagnostics offering that continues to attract significant interest. We remain committed to advancing point-of-care technologies that deliver meaningful clinical outcomes.”
Lumos sees strong early uptake for FebriDx in US rollout
Lumos recently reported encouraging early commercial progress for its FebriDx® rapid respiratory infection test in the United States, with reimbursement outcomes and customer adoption tracking positively following recent FDA CLIA waiver clearance.
More than 90% of submitted reimbursement claims have been paid to date, while average payments have exceeded the Medicare fee schedule benchmark of US$41.38 per test.
The early reimbursement performance is a positive signal for Lumos as it works to commercialise FebriDx in CLIA-waived healthcare settings, including urgent care and primary care clinics.
Lumos is using the lower-volume US spring and summer respiratory testing period to build market awareness, onboard new customers, progress pilot evaluations and refine reimbursement pathways ahead of the 2026/27 flu season.
The recent FDA CLIA waiver clearance was a key commercial milestone for FebriDx, as it enables broader use of the test in near-patient care environments.
FebriDx is designed to help healthcare providers rapidly assess respiratory infections at the point of care, supporting faster clinical decision-making during periods of high patient demand.
